New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
13:36 EDTNVONovo Nordisk says FDA approves NovoSeven RT for treatment of GT
Novo Nordisk announced the FDA has approved NovoSeven RT as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann's Thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets. Glanzmann's Thrombasthenia is a rare genetic bleeding disorder with limited treatment options. The safety and effectiveness of NovoSeven RT were demonstrated in the treatment of severe bleeding episodes and the perioperative management for major and minor surgical procedures for this specific patient population. The FDA approved NovoSeven RT for the treatment of GT based upon evidence collected from the global Glanzmann's Thrombasthenia Registry and the Hemostasis & Thrombosis Research Society Registry The data supported the effectiveness and safety of NovoSeven RT in the treatment of bleeding and for the prevention of bleeding during surgical procedures in patients with GT.
News For NVO From The Last 14 Days
Check below for free stories on NVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
13:23 EDTNVONovo Nordisk launches diabetes drug Ryzodeg in Mexico, Reuters says
Subscribe for More Information
August 31, 2014
14:04 EDTNVOWorldwide Business Research to hold a conference
Subscribe for More Information
August 26, 2014
10:18 EDTNVONovo Nordisk has no plans for large acquisitions, WSJ says
Lars Sorensen, the CEO of Denmark-based Novo Nordisk, says that despite the increased deal-making activity in the global pharmaceutical industry of late, Novo Nordisk has no plans to acquire any entity that it can't fund through its own cash flows, says the Wall Street Journal. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use